The role of radiography and MRI for eligibility assessment in DMOAD trials of knee OA

Frank W. Roemer, Chian K Kwoh, Daichi Hayashi, David T. Felson, Ali Guermazi

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Currently, no disease-modifying osteoarthritis drugs (DMOADs) have been approved. Past clinical trials have failed for several reasons, including the commonly applied definition of eligibility based on radiographic assessment of joint structure. In the context of precision medicine, finding the appropriate patient for a specific treatment approach will be of increasing relevance. Phenotypic stratification by use of imaging at the time of determining eligibility for clinical trials will be paramount and cannot be achieved using radiography alone. Furthermore, identification of joints at high risk of rapid progression of osteoarthritis is needed in order to enable a more efficient DMOAD trial design. In addition, joints at high risk of collapse need to be excluded at screening. The use of MRI might offer advantages over radiography in this context. Technological advances and simplified image assessment address many of the commonly perceived barriers to the application of MRI to assessment of eligibility for DMOAD clinical trials.

Original languageEnglish (US)
Pages (from-to)372-380
Number of pages9
JournalNature Reviews Rheumatology
Volume14
Issue number6
DOIs
StatePublished - Jun 1 2018

Fingerprint

Radiography
Osteoarthritis
Knee
Joints
Clinical Trials
Pharmaceutical Preparations
Precision Medicine
Drug Design
Therapeutics

ASJC Scopus subject areas

  • Rheumatology

Cite this

The role of radiography and MRI for eligibility assessment in DMOAD trials of knee OA. / Roemer, Frank W.; Kwoh, Chian K; Hayashi, Daichi; Felson, David T.; Guermazi, Ali.

In: Nature Reviews Rheumatology, Vol. 14, No. 6, 01.06.2018, p. 372-380.

Research output: Contribution to journalReview article

Roemer, Frank W. ; Kwoh, Chian K ; Hayashi, Daichi ; Felson, David T. ; Guermazi, Ali. / The role of radiography and MRI for eligibility assessment in DMOAD trials of knee OA. In: Nature Reviews Rheumatology. 2018 ; Vol. 14, No. 6. pp. 372-380.
@article{b8333db0ba5e48928067e76e8deb2499,
title = "The role of radiography and MRI for eligibility assessment in DMOAD trials of knee OA",
abstract = "Currently, no disease-modifying osteoarthritis drugs (DMOADs) have been approved. Past clinical trials have failed for several reasons, including the commonly applied definition of eligibility based on radiographic assessment of joint structure. In the context of precision medicine, finding the appropriate patient for a specific treatment approach will be of increasing relevance. Phenotypic stratification by use of imaging at the time of determining eligibility for clinical trials will be paramount and cannot be achieved using radiography alone. Furthermore, identification of joints at high risk of rapid progression of osteoarthritis is needed in order to enable a more efficient DMOAD trial design. In addition, joints at high risk of collapse need to be excluded at screening. The use of MRI might offer advantages over radiography in this context. Technological advances and simplified image assessment address many of the commonly perceived barriers to the application of MRI to assessment of eligibility for DMOAD clinical trials.",
author = "Roemer, {Frank W.} and Kwoh, {Chian K} and Daichi Hayashi and Felson, {David T.} and Ali Guermazi",
year = "2018",
month = "6",
day = "1",
doi = "10.1038/s41584-018-0010-z",
language = "English (US)",
volume = "14",
pages = "372--380",
journal = "Nature reviews. Rheumatology",
issn = "1759-4790",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - The role of radiography and MRI for eligibility assessment in DMOAD trials of knee OA

AU - Roemer, Frank W.

AU - Kwoh, Chian K

AU - Hayashi, Daichi

AU - Felson, David T.

AU - Guermazi, Ali

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Currently, no disease-modifying osteoarthritis drugs (DMOADs) have been approved. Past clinical trials have failed for several reasons, including the commonly applied definition of eligibility based on radiographic assessment of joint structure. In the context of precision medicine, finding the appropriate patient for a specific treatment approach will be of increasing relevance. Phenotypic stratification by use of imaging at the time of determining eligibility for clinical trials will be paramount and cannot be achieved using radiography alone. Furthermore, identification of joints at high risk of rapid progression of osteoarthritis is needed in order to enable a more efficient DMOAD trial design. In addition, joints at high risk of collapse need to be excluded at screening. The use of MRI might offer advantages over radiography in this context. Technological advances and simplified image assessment address many of the commonly perceived barriers to the application of MRI to assessment of eligibility for DMOAD clinical trials.

AB - Currently, no disease-modifying osteoarthritis drugs (DMOADs) have been approved. Past clinical trials have failed for several reasons, including the commonly applied definition of eligibility based on radiographic assessment of joint structure. In the context of precision medicine, finding the appropriate patient for a specific treatment approach will be of increasing relevance. Phenotypic stratification by use of imaging at the time of determining eligibility for clinical trials will be paramount and cannot be achieved using radiography alone. Furthermore, identification of joints at high risk of rapid progression of osteoarthritis is needed in order to enable a more efficient DMOAD trial design. In addition, joints at high risk of collapse need to be excluded at screening. The use of MRI might offer advantages over radiography in this context. Technological advances and simplified image assessment address many of the commonly perceived barriers to the application of MRI to assessment of eligibility for DMOAD clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=85046827082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046827082&partnerID=8YFLogxK

U2 - 10.1038/s41584-018-0010-z

DO - 10.1038/s41584-018-0010-z

M3 - Review article

VL - 14

SP - 372

EP - 380

JO - Nature reviews. Rheumatology

JF - Nature reviews. Rheumatology

SN - 1759-4790

IS - 6

ER -